Skip to main content
. Author manuscript; available in PMC: 2012 May 15.
Published in final edited form as: Bioorg Med Chem Lett. 2011 Mar 4;21(10):3152–3158. doi: 10.1016/j.bmcl.2011.02.114

Figure 3.

Figure 3

Dendrogram representation of the human kinome demonstrating kinase selectivity of reported inhibitors over a panel of 442 kinases. Activity for 45: Clk1 = 50 nM, Clk2 = 380 nM, Clk4 = 43 nM, Dyrk1A = 82 nM, PIP5K2C protein = 280 nM. Activity for 46: Clk1 = 18 nM, Clk2 = 59 nM, Clk4 = 5 nM, Dyrk1A = 13 nM, Dyrk1B = 300 nM, Dyrk2 = 480 nM, Erk8 = 430 nM, Mek5 = 47 nM, PIK3C2B protein = 340 nM, PIK3C2G protein = 40 nM, PIK3CG protein = 370 nM, PIP5K2C protein = 360 nM, Ysk4 = 190 nM. Activity for 54: Clk1 = 72 nM, Clk2 = 320 nM, Clk4 = 30 nM, Dyrk1A = 27 nM, PIK3C2B protein = 410 nM, PIK4CB protein = 430 nM, PIP5K2C protein = 310 nM. Data from DiscoveRx (http://kinomescan.com).

HHS Vulnerability Disclosure